Phase III Clinical Trials Nearing for Ventrus Biosciences, Inc. (VTUS)
While many biotechnology firms go for the “home run” by spending millions searching for viable solutions to ever-mutating strains of life-threatening diseases, others have taken the approach of focusing on smaller disorders that still have a great area of unmet need. There is certainly some prestige that attracts biotechnology investors as everyone is searching for the next great Lipitor-type drug or a viable therapy to effectively treat cancers, but for developmental biotechs, it is not always a great fit as the road less traveled is often where more success can be found. New York-based Ventus Biosciences, Inc., a specialty pharmaceutical…